share_log

Capricor Therapeutics Completes Submission Of Biologics License Application To FDA for Deramiocel

Capricor Therapeutics Completes Submission Of Biologics License Application To FDA for Deramiocel

Capricor Therapeutics 完成了向FDA提交生物制品许可申请的工作,针对Deramiocel。
Benzinga ·  01/02 06:16

-If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy-

-如果获得批准,deramiocel将成为第一个被批准用于杜氏肌营养不良症心肌病的疗法-

-BLA submission triggers $10 million milestone payment to Capricor from Nippon Shinyaku-

-BLA提交触发了来自日本信药的1000万美元里程碑支付给Capricor-

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发